secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0001193125-26-017164
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech to explore strategic alternatives including merger, sale, or liquidation
--------------------------------------------------------------------------------

- Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
- Further reduction-in-force and cost-cutting measures are also under consideration.
- No timetable for the process; no assurance any transaction will occur.
- IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/0001193125-26-017164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/d26457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-017164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer